Cook SJ - Search Results

1

ERK5 Signalling and Resistance to ERK1/2 Pathway Therapeutics: The Path Less Travelled?

Cook SJ, Lochhead PA. Cook SJ, et al. Front Cell Dev Biol. 2022 Jul 12;10:839997. doi: 10.3389/fcell.2022.839997. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35903549 Free PMC article. Review.

2

CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIMEL.

Gilley R, Lochhead PA, Balmanno K, Oxley D, Clark J, Cook SJ. Gilley R, et al. Among authors: cook sj. Cell Signal. 2012 Jan;24(1):170-80. doi: 10.1016/j.cellsig.2011.08.018. Epub 2011 Sep 8. Cell Signal. 2012. PMID: 21924351

3

ERK5 and its role in tumour development.

Lochhead PA, Gilley R, Cook SJ. Lochhead PA, et al. Among authors: cook sj. Biochem Soc Trans. 2012 Feb;40(1):251-6. doi: 10.1042/BST20110663. Biochem Soc Trans. 2012. PMID: 22260700 Review.

4

Mechanisms of acquired resistance to ERK1/2 pathway inhibitors.

Little AS, Smith PD, Cook SJ. Little AS, et al. Among authors: cook sj. Oncogene. 2013 Mar 7;32(10):1207-15. doi: 10.1038/onc.2012.160. Epub 2012 May 7. Oncogene. 2013. PMID: 22562245 Review.

5

A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr(286), not Thr(288).

Ashford AL, Oxley D, Kettle J, Hudson K, Guichard S, Cook SJ, Lochhead PA. Ashford AL, et al. Among authors: cook sj. Biochem J. 2014 Jan 1;457(1):43-56. doi: 10.1042/BJ20130461. Biochem J. 2014. PMID: 24134204

6

DYRK1A-mediated Cyclin D1 Degradation in Neural Stem Cells Contributes to the Neurogenic Cortical Defects in Down Syndrome.

Najas S, Arranz J, Lochhead PA, Ashford AL, Oxley D, Delabar JM, Cook SJ, Barallobre MJ, Arbonés ML. Najas S, et al. Among authors: cook sj. EBioMedicine. 2015 Jan 17;2(2):120-34. doi: 10.1016/j.ebiom.2015.01.010. eCollection 2015. EBioMedicine. 2015. PMID: 26137553 Free PMC article.

7

Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.

Ashford AL, Dunkley TP, Cockerill M, Rowlinson RA, Baak LM, Gallo R, Balmanno K, Goodwin LM, Ward RA, Lochhead PA, Guichard S, Hudson K, Cook SJ. Ashford AL, et al. Among authors: cook sj. Cell Mol Life Sci. 2016 Feb;73(4):883-900. doi: 10.1007/s00018-015-2032-x. Epub 2015 Sep 7. Cell Mol Life Sci. 2016. PMID: 26346493 Free PMC article.

8

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.

Lochhead PA, Clark J, Wang LZ, Gilmour L, Squires M, Gilley R, Foxton C, Newell DR, Wedge SR, Cook SJ. Lochhead PA, et al. Among authors: cook sj. Cell Cycle. 2016;15(4):506-18. doi: 10.1080/15384101.2015.1120915. Cell Cycle. 2016. PMID: 26959608 Free PMC article.

9

Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4.

Myers SM, Miller DC, Molyneux L, Arasta M, Bawn RH, Blackburn TJ, Cook SJ, Edwards N, Endicott JA, Golding BT, Griffin RJ, Hammonds T, Hardcastle IR, Harnor SJ, Heptinstall AB, Lochhead PA, Martin MP, Martin NC, Newell DR, Owen PJ, Pang LC, Reuillon T, Rigoreau LJM, Thomas HD, Tucker JA, Wang LZ, Wong AC, Noble MEM, Wedge SR, Cano C. Myers SM, et al. Among authors: cook sj. Eur J Med Chem. 2019 Sep 15;178:530-543. doi: 10.1016/j.ejmech.2019.05.057. Epub 2019 May 25. Eur J Med Chem. 2019. PMID: 31212132

10

Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors.

Lochhead PA, Tucker JA, Tatum NJ, Wang J, Oxley D, Kidger AM, Johnson VP, Cassidy MA, Gray NS, Noble MEM, Cook SJ. Lochhead PA, et al. Among authors: cook sj. Nat Commun. 2020 Mar 13;11(1):1383. doi: 10.1038/s41467-020-15031-3. Nat Commun. 2020. PMID: 32170057 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

244 results

Search Page